These results suggest that selective inhibition of HDAC3 could be useful in treatment of CTCL by disrupting DNA replication of the rapidly cycling tumor cells, ultimately leading to cell death. The gene discussed is HDAC3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.